---
document_datetime: 2025-12-29 11:45:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lupkynis.html
document_name: lupkynis.html
version: success
processing_time: 0.1105913
conversion_datetime: 2025-12-30 00:30:48.927285
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lupkynis

[RSS](/en/individual-human-medicine.xml/67608)

##### Authorised

This medicine is authorised for use in the European Union

voclosporin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lupkynis](#news-on)
- [More information on Lupkynis](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lupkynis is a medicine used to treat lupus nephritis, a manifestation of a disease called systemic lupus erythematosus. In lupus nephritis, the immune system (the body's natural defences) attacks the kidneys, causing inflammation and kidney damage.

Lupkynis is used together with another medicine called mycophenolate mofetil in adults with active class III, IV or V lupus nephritis, which are severe forms of the condition.

Lupkynis contains the active substance voclosporin.

Expand section

Collapse section

## How is Lupkynis used?

The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in diagnosing and treating lupus nephritis.

Lupkynis is available as a 7.9 mg capsule to be taken by mouth. The recommended dose is 23.7 mg (equivalent to three soft capsules) twice a day, with a minimum of 8 hours between each dose. The doctor should evaluate treatment effectiveness after about 24 weeks and weigh it against the risks to decide whether to continue treatment.

For more information about using Lupkynis, see the package leaflet or contact your doctor or pharmacist.

## How does Lupkynis work?

The active substance in Lupkynis, voclosporin, is an immunosuppressant (a medicine that reduces the activity of the immune system) known as a calcineurin inhibitor. This means that it blocks the action of calcineurin, an enzyme involved in activating T-lymphocytes (white blood cells that are part of the immune system and play a role in inflammation). By blocking the action of calcineurin, voclosporin reduces inflammation and other symptoms of lupus nephritis.

## What benefits of Lupkynis have been shown in studies?

Lupkynis was shown to be more effective than placebo (a dummy treatment) in achieving stable kidney function in adults with active lupus nephritis. A main study involving 357 adults found that after 52 weeks, 41% (73 out of 179) of patients taking Lupkynis had acceptable measures of both kidney function and protein in the urine (a sign of kidney damage) compared with 23% (40 out of 178) of patients receiving placebo. All patients received mycophenolate mofetil (another immunosuppressant medicine) in addition to Lupkynis or placebo.

## What are the risks associated with Lupkynis?

The most common side effects with Lupkynis (which may affect more than 1 in 10 people) are decreased glomerular filtration rate (a sign of kidney damage) and hypertension (high blood pressure).

The most common serious side effects with Lupkynis are infections, acute kidney injury and high blood pressure.

Lupkynis must not be used together with certain medicines called 'strong CYP3A4 inhibitors', including the antifungal medicines ketoconazole and itraconazole and the antibiotic medicine clarithromycin, as these may affect the levels of voclosporin in the blood.

For the full list of side effects and restrictions with Lupkynis, see the package leaflet.

## Why is Lupkynis authorised in the EU?

When used in combination with mycophenolate mofetil, Lupkynis has been shown to be effective in achieving stable kidney function in adults with active lupus nephritis. The medicine's side effect profile is serious and requires extensive monitoring of kidney function; adequate information on the risks and recommendations for monitoring is included in the product information. The European Medicines Agency therefore decided that Lupkynis's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Lupkynis?

The company will carry out a study to provide more information on the long-term safety of Lupkynis.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lupkynis have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lupkynis are continuously monitored. Suspected side effects reported with Lupkynis are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lupkynis

Lupkynis received a marketing authorisation valid throughout the EU on 15 September 2022.

Lupkynis : EPAR - Medicine overview

Adopted

Reference Number: EMEA/H/C/005256

English (EN) (118.99 KB - PDF)

**First published:** 20/09/2022

[View](/en/documents/overview/lupkynis-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-605)

български (BG) (135.58 KB - PDF)

**First published:**

20/09/2022

[View](/bg/documents/overview/lupkynis-epar-medicine-overview_bg.pdf)

español (ES) (110.41 KB - PDF)

**First published:**

20/09/2022

[View](/es/documents/overview/lupkynis-epar-medicine-overview_es.pdf)

čeština (CS) (130.83 KB - PDF)

**First published:**

20/09/2022

[View](/cs/documents/overview/lupkynis-epar-medicine-overview_cs.pdf)

dansk (DA) (108.54 KB - PDF)

**First published:**

20/09/2022

[View](/da/documents/overview/lupkynis-epar-medicine-overview_da.pdf)

Deutsch (DE) (113.42 KB - PDF)

**First published:**

20/09/2022

[View](/de/documents/overview/lupkynis-epar-medicine-overview_de.pdf)

eesti keel (ET) (98.73 KB - PDF)

**First published:**

20/09/2022

[View](/et/documents/overview/lupkynis-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.91 KB - PDF)

**First published:**

20/09/2022

[View](/el/documents/overview/lupkynis-epar-medicine-overview_el.pdf)

français (FR) (111.56 KB - PDF)

**First published:**

20/09/2022

[View](/fr/documents/overview/lupkynis-epar-medicine-overview_fr.pdf)

hrvatski (HR) (130.16 KB - PDF)

**First published:**

20/09/2022

[View](/hr/documents/overview/lupkynis-epar-medicine-overview_hr.pdf)

italiano (IT) (109.45 KB - PDF)

**First published:**

20/09/2022

[View](/it/documents/overview/lupkynis-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (148.44 KB - PDF)

**First published:**

20/09/2022

[View](/lv/documents/overview/lupkynis-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.38 KB - PDF)

**First published:**

20/09/2022

[View](/lt/documents/overview/lupkynis-epar-medicine-overview_lt.pdf)

magyar (HU) (130.24 KB - PDF)

**First published:**

20/09/2022

[View](/hu/documents/overview/lupkynis-epar-medicine-overview_hu.pdf)

Malti (MT) (133.31 KB - PDF)

**First published:**

20/09/2022

[View](/mt/documents/overview/lupkynis-epar-medicine-overview_mt.pdf)

Nederlands (NL) (109.73 KB - PDF)

**First published:**

20/09/2022

[View](/nl/documents/overview/lupkynis-epar-medicine-overview_nl.pdf)

polski (PL) (134.59 KB - PDF)

**First published:**

20/09/2022

[View](/pl/documents/overview/lupkynis-epar-medicine-overview_pl.pdf)

português (PT) (110.9 KB - PDF)

**First published:**

20/09/2022

[View](/pt/documents/overview/lupkynis-epar-medicine-overview_pt.pdf)

română (RO) (129.67 KB - PDF)

**First published:**

20/09/2022

[View](/ro/documents/overview/lupkynis-epar-medicine-overview_ro.pdf)

slovenčina (SK) (130.41 KB - PDF)

**First published:**

20/09/2022

[View](/sk/documents/overview/lupkynis-epar-medicine-overview_sk.pdf)

slovenščina (SL) (127.75 KB - PDF)

**First published:**

20/09/2022

[View](/sl/documents/overview/lupkynis-epar-medicine-overview_sl.pdf)

Suomi (FI) (107.93 KB - PDF)

**First published:**

20/09/2022

[View](/fi/documents/overview/lupkynis-epar-medicine-overview_fi.pdf)

svenska (SV) (108.37 KB - PDF)

**First published:**

20/09/2022

[View](/sv/documents/overview/lupkynis-epar-medicine-overview_sv.pdf)

Lupkynis : EPAR - Risk management plan

English (EN) (4.06 MB - PDF)

**First published:** 20/09/2022

**Last updated:** 25/07/2024

[View](/en/documents/rmp/lupkynis-epar-risk-management-plan_en.pdf)

## Product information

Lupkynis : EPAR - Product Information

English (EN) (468.71 KB - PDF)

**First published:** 20/09/2022

**Last updated:** 24/11/2025

[View](/en/documents/product-information/lupkynis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-656)

български (BG) (511.53 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/bg/documents/product-information/lupkynis-epar-product-information_bg.pdf)

español (ES) (459.19 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/es/documents/product-information/lupkynis-epar-product-information_es.pdf)

čeština (CS) (437.15 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/cs/documents/product-information/lupkynis-epar-product-information_cs.pdf)

dansk (DA) (477.86 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/da/documents/product-information/lupkynis-epar-product-information_da.pdf)

Deutsch (DE) (455.44 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/de/documents/product-information/lupkynis-epar-product-information_de.pdf)

eesti keel (ET) (465.62 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/et/documents/product-information/lupkynis-epar-product-information_et.pdf)

ελληνικά (EL) (518.24 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/el/documents/product-information/lupkynis-epar-product-information_el.pdf)

français (FR) (473.17 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/fr/documents/product-information/lupkynis-epar-product-information_fr.pdf)

hrvatski (HR) (459.36 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/hr/documents/product-information/lupkynis-epar-product-information_hr.pdf)

íslenska (IS) (440.97 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/is/documents/product-information/lupkynis-epar-product-information_is.pdf)

italiano (IT) (448.49 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/it/documents/product-information/lupkynis-epar-product-information_it.pdf)

latviešu valoda (LV) (479.56 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/lv/documents/product-information/lupkynis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (488.42 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/lt/documents/product-information/lupkynis-epar-product-information_lt.pdf)

magyar (HU) (500.49 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/hu/documents/product-information/lupkynis-epar-product-information_hu.pdf)

Malti (MT) (505.52 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/mt/documents/product-information/lupkynis-epar-product-information_mt.pdf)

Nederlands (NL) (446.28 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/nl/documents/product-information/lupkynis-epar-product-information_nl.pdf)

norsk (NO) (449.7 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/no/documents/product-information/lupkynis-epar-product-information_no.pdf)

polski (PL) (537.46 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/pl/documents/product-information/lupkynis-epar-product-information_pl.pdf)

português (PT) (446.66 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/pt/documents/product-information/lupkynis-epar-product-information_pt.pdf)

română (RO) (485.76 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/ro/documents/product-information/lupkynis-epar-product-information_ro.pdf)

slovenčina (SK) (481.22 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/sk/documents/product-information/lupkynis-epar-product-information_sk.pdf)

slovenščina (SL) (475.87 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/sl/documents/product-information/lupkynis-epar-product-information_sl.pdf)

Suomi (FI) (452.13 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/fi/documents/product-information/lupkynis-epar-product-information_fi.pdf)

svenska (SV) (458.11 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

24/11/2025

[View](/sv/documents/product-information/lupkynis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00011020/202501 17/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lupkynis : EPAR - All authorised presentations

English (EN) (12.99 KB - PDF)

**First published:** 20/09/2022

**Last updated:** 07/02/2023

[View](/en/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-635)

български (BG) (35.07 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/bg/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.15 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/es/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.38 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/cs/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.97 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/da/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.03 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/de/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.04 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/et/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (34.44 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/el/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_el.pdf)

français (FR) (10.99 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/fr/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (121.58 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/hr/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (10.92 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/is/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.42 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/it/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.67 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/lv/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.43 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/lt/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.81 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/hu/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (31.15 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/mt/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.98 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/nl/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (10.98 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/no/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.68 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/pl/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_pl.pdf)

português (PT) (11.12 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/pt/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.47 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/ro/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.18 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/sk/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (19.51 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/sl/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.32 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/fi/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (11.04 KB - PDF)

**First published:**

20/09/2022

**Last updated:**

07/02/2023

[View](/sv/documents/all-authorised-presentations/lupkynis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lupkynis Active substance voclosporin International non-proprietary name (INN) or common name voclosporin Therapeutic area (MeSH) Lupus Nephritis Anatomical therapeutic chemical (ATC) code L04AD03

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

## Authorisation details

EMA product number EMEA/H/C/005256

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Otsuka Pharmaceutical Netherlands B.V.

Herikerbergweg 292

Opinion adopted 21/07/2022 Marketing authorisation issued 15/09/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lupkynis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (123.22 KB - PDF)

**First published:** 19/06/2025

**Last updated:** 24/11/2025

[View](/en/documents/procedural-steps-after/lupkynis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lupkynis : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (104.7 KB - PDF)

**First published:** 07/02/2023

**Last updated:** 19/06/2025

[View](/en/documents/procedural-steps-after/lupkynis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Lupkynis-PSUSA-00011020-202501 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMADOC-1700519818-2639887

English (EN) (162.24 KB - PDF)

**First published:** 24/11/2025

[View](/en/documents/scientific-conclusion/lupkynis-psusa-00011020-202501-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Lupkynis-H-C-PSUSA-00011020-202401 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/552100/2024

English (EN) (93.5 KB - PDF)

**First published:** 27/11/2024

[View](/en/documents/scientific-conclusion/lupkynis-h-c-psusa-00011020-202401-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Lupkynis : EPAR - Public Assessment report

Adopted

Reference Number: EMA/681286/2022

English (EN) (3.73 MB - PDF)

**First published:** 20/09/2022

[View](/en/documents/assessment-report/lupkynis-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lupkynis

Adopted

Reference Number: EMA/CHMP/623061/2022

English (EN) (116.26 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lupkynis_en.pdf)

#### News on Lupkynis

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

#### More information on Lupkynis

- [An observational post-authorisation safety study (PASS) in Europe to further characterise and quantify long-term safety profile with respect to neurotoxicity, chronic nephrotoxicity, and malignancy with use of voclosporin - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000284)

**This page was last updated on** 24/11/2025

## Share this page

[Back to top](#main-content)